{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:38:25Z","timestamp":1789540705534,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","schres-journal.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.schres.2017.05.004","type":"journal-article","created":{"date-parts":[[2017,5,6]],"date-time":"2017-05-06T20:31:05Z","timestamp":1494102665000},"page":"26-31","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Evidence for differential opioid use disorder in schizophrenia in an addiction treatment population"],"prefix":"10.1016","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6121-7439","authenticated-orcid":false,"given":"Joshua","family":"Chiappelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Hackman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Elliot Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.schres.2017.05.004_bb0005","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nrn3104","article-title":"Opiate versus psychostimulant addiction: the differences do matter","volume":"12","author":"Badiani","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"issue":"9","key":"10.1016\/j.schres.2017.05.004_bb8424","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1176\/ajp.142.9.1106","article-title":"Effect of methadone plus neuroleptics on treatment-resistant chronic paranoid schizophrenia","volume":"142","author":"Brizer","year":"1985","journal-title":"Am. J. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2017.05.004_bb0010","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1523\/JNEUROSCI.22-07-02977.2002","article-title":"Role of dopamine D2-like receptors in cocaine self-administration: studies with D2 receptor mutant mice and novel D2 receptor antagonists","volume":"22","author":"Caine","year":"2002","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.schres.2017.05.004_bb0015","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0006-3223(01)01134-9","article-title":"A neurobiological basis for substance abuse comorbidity in schizophrenia","volume":"50","author":"Chambers","year":"2001","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2017.05.004_bb0133","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1192\/bjp.bp.107.041228","article-title":"Brain dopamine response in human opioid addiction","volume":"193","author":"Daglish","year":"2008","journal-title":"Br. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2017.05.004_bb0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/schbul\/16.1.69","article-title":"Acute effects of drug abuse in schizophrenic patients: clinical observations and patients' self-reports","volume":"16","author":"Dixon","year":"1990","journal-title":"Schizophr. Bull."},{"issue":"2","key":"10.1016\/j.schres.2017.05.004_bb0025","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1176\/ajp.148.2.224","article-title":"Drug abuse in schizophrenic patients: clinical correlates and reasons for use","volume":"148","author":"Dixon","year":"1991","journal-title":"Am. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2017.05.004_bb0030","doi-asserted-by":"crossref","first-page":"RC224","DOI":"10.1523\/JNEUROSCI.22-10-j0004.2002","article-title":"Failure of intravenous morphine to serve as an effective instrumental reinforcer in dopamine D2 receptor knock-out mice","volume":"22","author":"Elmer","year":"2002","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.schres.2017.05.004_bb8953","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00213-005-0051-2","article-title":"Brain stimulation and morphine reward deficits in dopamine D2 receptor-deficient mice","volume":"182","author":"Elmer","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.schres.2017.05.004_bb0035","first-page":"393","article-title":"Psychosis and drug dependence: results from a national survey of prisoners. Br. J","volume":"181","author":"Farrell","year":"2002","journal-title":"Psychiatry"},{"issue":"7069","key":"10.1016\/j.schres.2017.05.004_bb6035","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/nature04172","article-title":"Morphine reward in dopamine-deficient mice","volume":"438","author":"Hnasko","year":"2005","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.schres.2017.05.004_bb0040","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/15504263.2013.867199","article-title":"Opiate dependence in schizophrenia: case presentation and literature review","volume":"10","author":"Kern","year":"2014","journal-title":"J. Dual. Diagn."},{"issue":"7","key":"10.1016\/j.schres.2017.05.004_bb0045","doi-asserted-by":"crossref","first-page":"e642","DOI":"10.4088\/JCP.12r08178","article-title":"Antipsychotics for primary alcohol dependence: a systematic review and meta-analysis of placebo-controlled trials","volume":"74","author":"Kishi","year":"2013","journal-title":"J. Clin. Psychiatry"},{"issue":"3-4","key":"10.1016\/j.schres.2017.05.004_bb6072","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF03033360","article-title":"The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia","volume":"10","author":"Krystal","year":"2006","journal-title":"Neurotox. Res."},{"issue":"5","key":"10.1016\/j.schres.2017.05.004_bb0050","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/nrn3939","article-title":"The dopamine theory of addiction: 40 years of highs and lows","volume":"16","author":"Nutt","year":"2015","journal-title":"Nat. Rev. Neurosci."},{"issue":"19","key":"10.1016\/j.schres.2017.05.004_bb0055","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1001\/jama.1990.03450190043026","article-title":"Comorbidity of mental disorders with alcohol and other drug abuse. Results from the epidemiologic catchment area (ECA) study","volume":"264","author":"Regier","year":"1990","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.schres.2017.05.004_bb0060","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/00005053-198711000-00001","article-title":"A review of psychoactive substance use and abuse in schizophrenia. Patterns of drug choice","volume":"175","author":"Schneier","year":"1987","journal-title":"J. Nerv. Ment. Dis."},{"issue":"10","key":"10.1016\/j.schres.2017.05.004_bb1299","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1176\/ajp.144.10.1340","article-title":"Antipsychotic effect of buprenorphine in schizophrenia","volume":"144","author":"Schmauss","year":"1987","journal-title":"Am. J. Psychiatry."},{"issue":"11","key":"10.1016\/j.schres.2017.05.004_bb0065","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1097\/j.pain.0000000000000304","article-title":"Decreased pain sensitivity among people with schizophrenia: a meta-analysis of experimental pain induction studies","volume":"156","author":"Stubbs","year":"2015","journal-title":"Pain"},{"issue":"1\u20132","key":"10.1016\/j.schres.2017.05.004_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neulet.2005.11.050","article-title":"Trifluoperazine, an orally available clinically used drug, disrupts opioid antinociceptive tolerance","volume":"397","author":"Tang","year":"2006","journal-title":"Neurosci. Lett."},{"issue":"2","key":"10.1016\/j.schres.2017.05.004_bb0075","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/syn.21500","article-title":"Olanzapine suppresses the rewarding and discriminative stimulus effects induced by morphine","volume":"66","author":"Torigoe","year":"2012","journal-title":"Synapse"},{"key":"10.1016\/j.schres.2017.05.004_bb0080","article-title":"Substance Abuse and Mental Health Services Administration. Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set \u2014 Discharges (TEDS-D)","author":"United States Department of Health and Human Services","year":"2011"},{"key":"10.1016\/j.schres.2017.05.004_bb0085","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.2147\/NDT.S87666","article-title":"Pain perception in schizophrenia: influence of neuropeptides, cognitive disorders, and negative symptoms","volume":"11","author":"Urban-Kowalczyk","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"2\u20133","key":"10.1016\/j.schres.2017.05.004_bb0090","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.psychres.2012.05.028","article-title":"Assessing illicit drug use among adults with schizophrenia","volume":"200","author":"Van Dorn","year":"2012","journal-title":"Psychiatry Res."},{"issue":"5","key":"10.1016\/j.schres.2017.05.004_bb0095","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/cercor\/bhr202","article-title":"Cortical opioid markers in schizophrenia and across postnatal development","volume":"22","author":"Volk","year":"2012","journal-title":"Cereb. Cortex"},{"issue":"3","key":"10.1016\/j.schres.2017.05.004_bb0100","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/schbul\/sbp016","article-title":"Substance use disorders in schizophrenia\u2014clinical implications of comorbidity","volume":"35","author":"Volkow","year":"2009","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2017.05.004_bb0105","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1124\/jpet.110.175539","article-title":"Haloperidol disrupts opioid-antinociceptive tolerance and physical dependence","volume":"338","author":"Yang","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417302633?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996417302633?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T12:57:33Z","timestamp":1692795453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996417302633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":27,"alternative-id":["S0920996417302633"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2017.05.004","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence for differential opioid use disorder in schizophrenia in an addiction treatment population","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2017.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}